NEVVI Medicare utilization intelligence

← back

Provider profile

VOLETI, VINOD M.D.

Ophthalmology · NPI 1245452804 · MORRISTOWN, NJ

1
Groups
20
Codes · 2024
34,558
Disclosed services

VOLETI, VINOD is a Ophthalmology in MORRISTOWN, NJ, a member of 1 medical group, who billed 20 distinct codes to Medicare Part B in 2024.

Groups: ASSOCIATED RETINAL CONSULTANTS LLC (TEANECK, NJ)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

34,558
disclosed services
20
codes billed to Medicare Part B
Prior year · CY2023 29,334 disclosed services

This provider's disclosed Medicare payments across all codes were premium in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J2777 Injection, faricimab-svoa, 0.1 mg premiumpremium premiumpremium
J0177 Injection, aflibercept hd, 1 mg premiumpremium premiumpremium
J2781 Injection, pegcetacoplan, intravitreal, 1 mg premiumpremium premiumpremium
92134 Imaging of retina premiumpremium premiumpremium
Q5128 Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg premiumpremium premiumpremium
92014 Established patient complete exam of visual system premiumpremium premiumpremium
67028 Injection of drug into eye premiumpremium premiumpremium
92202 Extended exam of the back part of the eye with optic nerve drawing premiumpremium premiumpremium
J0178 Injection, aflibercept, 1 mg premiumpremium premiumpremium
92012 Established patient problem focused exam of visual system premiumpremium premiumpremium
92201 Extended exam of the back part of the eye with retinal drawing premiumpremium premiumpremium
J3590 Unclassified biologics premiumpremium premiumpremium
99426 Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month premiumpremium premiumpremium
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more premiumpremium premiumpremium
92250 Photography of the retina premiumpremium premiumpremium
99427 Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month premiumpremium premiumpremium
92235 Exam of retinal blood vessels using a special camera after injection of a dye premiumpremium premiumpremium
76512 2d ultrasound scan of eye tissue and structures premiumpremium premiumpremium
67145 Photocoagulation treatment to prevent detachment of retina premiumpremium premiumpremium
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more premiumpremium premiumpremium

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.